LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

10X Genomics Inc (Class A)

Closed

SectorHealthcare

13.48 -3.02

Overview

Share price change

24h

Current

Min

13.26

Max

13.93

Key metrics

By Trading Economics

Income

69M

35M

Sales

18M

173M

EPS

0.48

Profit margin

19.975

Employees

1,306

EBITDA

86M

47M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+7.04% upside

Dividends

By Dow Jones

Next Earnings

28 Oct 2025

Market Stats

By TradingEconomics

Market Cap

60M

1.7B

Previous open

16.5

Previous close

13.48

News Sentiment

By Acuity

34%

66%

121 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

10X Genomics Inc (Class A) Chart

Past performance is not a reliable indicator of future results.

Related News

8 Sept 2025, 23:59 UTC

Acquisitions, Mergers, Takeovers

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 Sept 2025, 22:02 UTC

Major Market Movers

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 Sept 2025, 17:01 UTC

Major Market Movers

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 Sept 2025, 17:01 UTC

Major Market Movers

Tron Shares Rise After New Investment From Bravemorning

8 Sept 2025, 16:14 UTC

Major Market Movers

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 Sept 2025, 16:13 UTC

Major Market Movers

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 Sept 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 Sept 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8 Sept 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 Sept 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8 Sept 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 Sept 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 Sept 2025, 21:47 UTC

Major Market Movers

Microsoft Signs $17.4B AI Deal With Nebius

8 Sept 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 Sept 2025, 21:20 UTC

Acquisitions, Mergers, Takeovers

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 Sept 2025, 21:19 UTC

Acquisitions, Mergers, Takeovers

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 Sept 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 Sept 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

8 Sept 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 Sept 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 Sept 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 Sept 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 Sept 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 Sept 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8 Sept 2025, 16:59 UTC

Market Talk
Acquisitions, Mergers, Takeovers

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 Sept 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 Sept 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 Sept 2025, 16:16 UTC

Earnings

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 Sept 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 Sept 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer Comparison

Price change

10X Genomics Inc (Class A) Forecast

Price Target

By TipRanks

7.04% upside

12 Months Forecast

Average 14.91 USD  7.04%

High 17 USD

Low 13 USD

Based on 12 Wall Street analysts offering 12 month price targets for10X Genomics Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

12 ratings

5

Buy

7

Hold

0

Sell

Technical Score

By Trading Central

8.32 / 8.63Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

121 / 371 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
help-icon Live chat